COMMUNIQUÉS West-GlobeNewswire

-
Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale
17/04/2024 -
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
17/04/2024 -
Treace to Present at Bank of America Health Care Conference
17/04/2024 -
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17/04/2024 -
Tilray Brands Lights Up 420 With Music Festivals and Celebrations Across The Country
17/04/2024 -
Medigene to Present at Upcoming Scientific Conferences
17/04/2024 -
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
17/04/2024 -
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17/04/2024 -
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17/04/2024 -
Q1 2024 Revenue and Business Update
17/04/2024 -
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
17/04/2024 -
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17/04/2024 -
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17/04/2024 -
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17/04/2024 -
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
17/04/2024 -
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
17/04/2024 -
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques
17/04/2024 -
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17/04/2024 -
Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives
17/04/2024
Pages